Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin II–Induced Hypertensive Rats

It is unknown whether long-term pharmacological stimulation of soluble guanylate cyclase (sGC), elevating intracellular cGMP levels, has a beneficial effect on hypertension. The purpose of this study is to investigate the effects of BAY41-2272, an orally available sGC stimulator, on cardiovascular r...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2006-11, Vol.48 (5), p.972-978
Main Authors: Masuyama, Hiroyuki, Tsuruda, Toshihiro, Kato, Johji, Imamura, Takuroh, Asada, Yujiro, Stasch, Johannes-Peter, Kitamura, Kazuo, Eto, Tanenao
Format: Article
Language:English
Subjects:
Angiotensin II - administration & dosage
Angiotensin II - pharmacology
Animals
Cardiomegaly - chemically induced
Cardiomegaly - drug therapy
Cardiomegaly - physiopathology
Cardiovascular System - drug effects
Cardiovascular System - enzymology
Cells, Cultured
Guanylate Cyclase - blood
Guanylate Cyclase - metabolism
Guanylate Cyclase - physiology
Hypertension - drug therapy
Hypertension - enzymology
Hypertension - physiopathology
Male
Pyrazoles - administration & dosage
Pyrazoles - pharmacology
Pyridines - administration & dosage
Pyridines - pharmacology
Rats
Rats, Wistar
Solubility
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is unknown whether long-term pharmacological stimulation of soluble guanylate cyclase (sGC), elevating intracellular cGMP levels, has a beneficial effect on hypertension. The purpose of this study is to investigate the effects of BAY41-2272, an orally available sGC stimulator, on cardiovascular remodeling in hypertensive rats. Eight-week-old male Wistar rats with hypertension induced by angiotensin II infused subcutaneously at 250 ng/kg per minute were treated orally with a low ([L] 2 mg/kg per day) or high ([H] 10 mg/kg per day) dose of BAY41-2272 for 14 days. BAY41-2272-H partially suppressed the rise in blood pressure and reduced the heart weight (4.20±0.34 versus 3.68±0.20 mg/g; P
ISSN:0194-911X
1524-4563
DOI:10.1161/01.HYP.0000241087.12492.47